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Abstract: Breast cancer is characterized by a series of genetic mutations and is therefore ideally 
placed for gene therapy intervention. The aim of gene therapy is to deliver a nucleic acid-based 
drug to either correct or destroy the cells harboring the genetic aberration. More recently, cancer 
gene therapy has evolved to also encompass delivery of RNA interference technologies, as well 
as cancer DNA vaccines. However, the bottleneck in creating such nucleic acid pharmaceuticals 
lies in the delivery. Deliverability of DNA is limited as it is prone to circulating nucleases; 
therefore, numerous strategies have been employed to aid with biological transport. This review 
will discuss some of the viral and nonviral approaches to breast cancer gene therapy, and pres-
ent the findings of clinical trials of these therapies in breast cancer patients. Also detailed are 
some of the most recent developments in nonviral approaches to targeting in breast cancer gene 
therapy, including transcriptional control, and the development of recombinant, multifunctional 
bio-inspired systems. Lastly, DNA vaccines for breast cancer are documented, with comment 
on requirements for successful pharmaceutical product development.
Keywords: breast cancer, gene therapy, nonviral, clinical trial
Introduction
There are in theory a plethora of targets available for breast cancer gene therapy, yet 
at the time of writing this review article, there are still no approved gene therapy prod-
ucts for breast cancer. Over 63% of all gene therapy clinical trials are in the field of 
cancer, so it could be extrapolated that a clinical product should ensue in due course. 
Yet the more that is known about the genetic dysregulation of the various subtypes of 
breast cancer, the more difficult it becomes to select a genetic therapy. The European 
Commission (EC) 2003/63 directive states that a gene therapy medicinal product is 
essentially a piece of nucleic acid that is delivered either in vivo or ex vivo that can 
be prophylactic, diagnostic, or therapeutic.1 This then opens the field up to encompass 
traditional corrective genes, cytotoxic genes, small interfering RNA (siRNA) or short 
hairpin RNA (shRNA) interference therapies, microRNA up- or downregulation, and 
DNA vaccination against overexpressed tumor antigens. Virtually all of these genetic 
therapies require assistance to overcome the many extra- and intracellular biological 
barriers. Therefore, for successful nucleic acid transfer, a delivery system must be 
considered that is typically either viral or nonviral. Taking all of these factors on board, 
it becomes apparent that the potential options for the “gene therapist” are actually 
limitless and with no clear “frontrunner”, it is not surprising that the progress of a 
therapy is moderate at best. The scope of this breast cancer review is to consider the 
progress that has been made with nucleic acid therapies, to examine possible future 
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targets, and to identify some of the key challenges that are 
preventing product approval.
Viral breast cancer gene therapy
Viruses are highly efficient at transducing cells with their 
genetic material and so provide excellent delivery systems 
for the purposes of gene therapy. Recombinant viruses are 
nonreplicative, require a packaging cell line for particle 
production, and have been genetically engineered to carry 
the gene of interest. Increasingly, viral characteristics must 
be paired with the disease target (Table 1). 
Retroviral viruses and breast cancer
Retroviral vectors are characterized by integration into the 
host genome and although this evokes long-term transgene 
expression, there are also some safety concerns with inser-
tional mutagenesis and activation of oncogenes in normal 
tissues. However, if gene expression can be targeted only 
to tumors then recombinant retroviral vectors can be suc-
cessfully employed. Expression may be controlled by direct 
intratumoral injection, although a significant limitation is 
that this strategy is only viable for accessible tumors. For 
example, MetXia-P450 is a recombinant retroviral vector that 
delivers cytochrome P450 2B6 in a gene-directed enzyme 
prodrug therapy (GDEPT) strategy to improve metabolism 
of cyclophosphamide (CPA). Initial preclinical studies 
determined that MetXia-P450 sensitized T47D breast cancer 
cells to CPA, produced a bystander effect, and significantly 
reduced growth of MDA-MB-231 breast tumors in vivo.2 
MetXia-P450 entered Phase I clinical trials for nine breast 
cancer and three melanoma patients with cutaneous tumors 
to evaluate safety and then clinical response.3 After two 
intratumoral injections of MetXia-P450 and treatment with 
CPA, one breast cancer patient had a partial response and 
four had stable disease over the 12-week period. Although 
less than 1% of tumor cells were transduced, in this trial, 
16/24 biopsies were positive for the β-galactosidase 
expression. Even with such a low transduction, the observed 
antitumor activity has led to further clinical trials for patients 
with pancreatic cancer.
Alternatively, the recombinant retrovirus may have a 
targeting motif for tumors, thus enabling systemic admin-
istration to less accessible metastases. Rexin-G is a highly 
engineered retroviral nanoparticle that achieves targeting 
to cancerous lesions through the attachment of a collagen 
motif that binds to “newly exposed” extracellular matrix, 
which is typically associated with tumor tissue. The 
transgene employed is a cytotoxic “dominant negative” 
cyclin G1 gene that results in tumor apoptosis and disrupts 
proliferation of the tumor vasculature.4 This therapy has 
entered several clinical trials with Phase I/II completed for 
metastatic breast cancer, and the authors have highlighted 
several noteworthy solid tumor cases.5 One such example 
was that of a 74-year-old woman who was diagnosed in 2001 
with infiltrating ductal carcinoma of breast, stage T3N2. The 
patient went through a series of treatment regimens where 
following initial response, chemoresistant disease resulted, 
which was confirmed in 2006. Tumors were evident in the 
lymph node and anterior chest wall. In 2007, Rexin-G was 
administered three times a week for 3 weeks at a dose of 
1×1011 particles. Regression of the tumors enabled surgical 
resection of a solitary residual tumor, which was a fibrotic 
mass with evidence of apoptosis and tumor-infiltrating CD8+ 
T-cells, again indicative of a good prognosis. This was fur-
ther evidenced by patient survival in excess of 3 years at the 
time the authors published. Gordon and Hall give several 
other remarkable examples of the success of their therapy, 
which has been attributed to having a stealth nanoparticle 
that does not evoke an immune response, can be repeatedly 
administered, exploits retroviral characteristics with a tropism 
for only dividing cells thus sparing normal tissue damage, 
and confers widespread anticancer activity by blocking the 
cell cycle in G1.5
Oncolytic herpes simplex virus and 
breast cancer
The therapeutic potential of utilizing viruses that selectively 
replicate and destroy cancer cells is gaining momentum. Apart 
from having a tropism for cancer cells, oncolytic viruses can 
also be designed to deliver a transgene in addition to their 
cytotoxic capacity.6 The herpes simplex virus-1 (HSV-1) was 
genetically engineered to create the attenuated HF10 clone.7 
Early preclinical tests with the MM102-TC breast cancer 
tumors in vivo were very promising, with HF10-treated 
mice surviving up to 120 days, .40 days longer than control 
mice after intratumoral injection.8,9 These promising mouse 
assays led to clinical trialing of the therapy, in which HF10 
was injected into the cutaneous or subcutaneous nodules of 
six patients with recurrent breast cancer.9 For each patient, 
two nodules were selected, one of which received a saline 
control, the other an injection of HF10 (dose ranged from 
104–5×105 pfu/0.5 mL). The injections were given daily for 
3 days at various sites to ensure good distribution. After 2 
weeks, the tumors were excised for histopathological examina-
tion. There were no local or systemic adverse effects following 
treatment and tumor  regression of 30%–100% was observed.9 
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Furthermore, mean counts of CD8-infiltrating lymphocytes 
were significantly higher.10
Although initial clinical trials have been encouraging, 
delivery of the HF10 virus has been local-regional, and as 
yet, the systemic effects of this therapy have not been evalu-
ated for breast cancer patients. Concerns over widespread 
delivery of HF10 may be alleviated by the fact that the HSV 
virus does not integrate into the host genome, thus avoiding 
unwanted mutations; should normal tissue replication occur, 
retroviral drugs could be employed to control the virus. Of 
course, extensive preclinical testing would be required before 
considering systemic delivery, but given how difficult distant 
metastases are to treat, a targeted oncolytic virus could poten-
tially have very high rewards for breast cancer, in a similar 
manner to myeloma patients with disseminated disease.11
Oncolytic viruses can also have a dual function through 
delivery of an immune activating transgene, as is the case 
with talimogene laherparepvec (T-VEC [OncoVEXGM-CSF]).12 
This oncolytic HSV expresses granulocyte-macrophage 
colony-stimulating factor (GM-CSF), which leads to an anti-
tumor immune response.13 As with most HSVs, the deletion 
of the ICP34.5 gene confers tumor selectivity. The second 
 generation T-VEC is designed to be more potent but still have 
the safety profile of the previous HSVs, which have been well-
tolerated in the clinic.14–16 The main difference in the second 
generation was deletion of the ICP47 gene in order to enable 
antigen presentation on HSV-infected cells.12 Thirty patients 
with either cutaneous or subcutaneous metastases from a 
range of primary sites were selected, including those with 
breast cancer. Thirteen patients received a single dose and 
17 received three doses. The main side effects were mild flu-
like symptoms and local reactions at the injection site, which 
could be linked to the expression of GM-CSF. This local 
inflammation was dose-limiting and the study was amended 
in HSV-seronegative patients to a maximum of 107 pfu/mL. 
Of the 26 tumor biopsies, 14 stained for tumor necrosis, 
which correlated with HSV expression. The authors conclude 
that T-VEC is well-tolerated and can be safely administered 
with evidence of an antitumor effect.12 The question then still 
remains as to whether T-VEC could be administered systemi-
cally to target and destroy disseminated disease.
There are several oncolytic viruses in the pipeline; for 
example, one has been designed that targets breast cancer 
brain metastases, again with an immunotherapy approach.17 
The oncolytic HSV (M002) has deletions in both copies of 
the y
1
34.5 gene, thus conferring specificity by only replicat-
ing in tumor cells. The M002 virus has also been engineered 
to express interleukin (IL)-12, a known proinflammatory 
cytokine that confers an antitumor effect.18 The tumor 
microenvironment is heterogenous and so by delivering 
IL-12, the authors hope to eradicate uninfected tumor cells 
through immunotherapy. Results indicated that the levels 
of IL-12 produced following infection with M002 in vitro 
were at desired physiological levels. Perhaps more impor-
tantly though, analysis in vivo demonstrated that M002 
significantly improved survival and reduced tumor burden 
over the R3659 virus, which did not express IL-12.17 This 
supports the dual functionality of combining lytic activity 
with immunotherapy.
Oncolytic parvovirus and breast cancer
The rodent parvovirus-H1 (H1-PV) selectively replicates 
in tumor cells and is not known to evoke pathogenicity in 
humans.19 Although the H1-PV has been shown to enter 
both normal and cancerous cells, it can only fully replicate 
its life cycle in the latter.20 In addition, the H1-PV can also 
activate the immune system via toll-like receptors 3 and 9 and 
cause NF-κB-dependent activation of the adaptive immune 
response.21 To evaluate the tropism of the H1-PV virus fur-
ther, Muharram et al evaluated the cytotoxicity in 96 tumors 
taken from breast cancer patients with normal cells taken 
from the patients’ peritumoral tissue as a negative control.22 
The clinical samples were taken prior to any other anticancer 
therapy. Of the 69 samples that gave cultures, sensitivity to 
the H1-PV was strongly correlated with high-grade tumors 
(48%). The authors also note the higher multiplicity of infec-
tion (MOI) that is required compared to routine in vitro cell 
lines.22 This study clearly highlights the benefits of using 
clinical breast tumors when evaluating the infectivity of the 
H1-PV. The lack of activation in the normal peritumoral tis-
sue further confirms the selectivity of the H1-PV for higher-
grade breast cancer tumors (.2). The tropism for aggressive 
breast cancer tissue should open up a plethora of therapeutic 
options, especially for those patients with limited treatment 
options. Parvoviruses are also attractive because they have 
been utilized as potent chemosensitizers, for example, with 
gemcitabine for pancreatic cancer, and could be employed 
with conventional therapies.23 In addition, the H1-PV has 
been genetically engineered to deliver complementary DNA 
(cDNA) immunotherapy such as TNFα and IFN-γ, thereby 
improving therapeutic outcomes.24
Challenges
The development of viral gene therapies have been somewhat 
limited for those patients with breast cancer, with the vast 
majority of trials to date focused on proof of principle in 
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highly accessible cutaneous tumors. While these studies need 
to be completed, there is a dearth in the literature of experi-
ments that go beyond intratumoral injection. Disseminated 
breast cancer is far from accessible, and therefore, studies 
with systemic administration of viral gene therapies are 
critical if progress is to be realized. The two major hurdles 
that need to be overcome are: 1) ensuring that viruses can 
be targeted by providing evidence in vivo and clinically in 
patients, and 2) that when the virus gets to its target site, the 
infectivity rate will be high enough to generate a significant 
therapeutic effect, while lacking immunogenicity.
Reovirus therapy has provided impressive therapeutic 
results in mouse models of experimental breast cancer. The 
progress of the reovirus arose from exciting preclinical data 
that demonstrated a therapy that could target distant tumors. 
Delivered systemically, replication of the virus is limited 
to cancer cells, and provoked regression of tumors at sites 
distant to the site of delivery in an MDA-MB-468 bilateral 
tumor model. Moreover, the reovirus was capable of repli-
cation in surgical breast tumor explants.25 The virus is only 
known to replicate in cancer cells that have an activated Ras 
pathway. Another reovirus, Reolysin® (Oncolytics Biotech, 
Inc., Calgary, AB, Canada) was administered for the first 
time in the US intravenously to 18 patients with advanced 
solid tumors, two of whom had breast cancer. This was a 
multiple-dosing experiment every 28 days to determine the 
maximally tolerated dose. The virus was relatively well-
tolerated, with the majority having grade 1 toxicities. Only 
two patients had grade 2 toxicities, one of whom following 
seven administrations of 1×1010 viral particles.26 From trials 
such as this, it is invaluable to know that all toxicities were 
resolved with time and were mild compared to conventional 
chemotherapy. Unfortunately, all patients developed neutral-
izing antibodies that may restrict long-term administration 
of this oncolytic virus, but at the same time, this information 
points researchers in the right direction to further improve 
the therapy. Although clinical outcome was not the endpoint, 
one patient with chemoresistant metastatic breast cancer had 
a partial response with a 34% reduction in tumor burden. 
This patient also had a Ras mutation, supporting the premise 
of reovirus selective targeting.26 The constant shrinkage in 
tumor volume was maintained for 9 weeks, which provides 
important information when scheduling the dose and timing 
of such novel nucleic acid therapeutics. Similar results were 
also reported from systemic delivery of the reovirus in two 
trials in the UK.27,28 This gives researchers in the field confi-
dence and the necessary clinical data to drive  development 
of this therapy forward. Subsequently, at the time of  writing 
this review, Oncolytics Biotech, Inc. have 23 clinical trials 
ongoing for Reolysin®. IND213 is one such trial, which com-
bines intravenous administration of Reolysin® in combina-
tion with paclitaxel for patients with advanced or metastatic 
breast cancer.
With respect to breast cancer, preclinical in vivo experi-
ments with viruses must be designed to demonstrate maximal 
targeting of the tumor in order for the therapy to progress 
into the clinic. For example, Nanni et al delivered a human 
epidermal growth factor receptor 2 (HER-2) targeted 
oncolytic virus for breast cancer and demonstrated efficacy 
in vivo following intraperitoneal administration.29 Taking 
on board new results is also critical to success. Oncolytic 
HSVs are hampered by poor potency in the clinic; studies 
by Cody et al that highlight the value of including histone 
deacetylase inhibitors to improve viral transcription could 
have key knock-on effects to those researching advanced 
development of HSVs.30
Development of a therapeutic product will only happen 
through the generation of translational data that at the earliest 
stages is designed for the end target, namely patients. Once 
in the clinic, data that demonstrates successful systemic 
administration coupled with a therapeutic response in patients 
will undoubtedly have the biggest impact in the drive toward 
a licensed viral therapy.
Nonviral breast cancer gene 
therapy
Typically, the delivery of genetic material involves either 
physical methods such as injection or gene gun, or chemical 
methods of delivery. Some physical methods of gene transfer 
have been assessed at clinical trial for breast cancer. Naked 
reporter plasmid DNA (pDNA) (LacZ) was successfully 
delivered by a needle-free jet injection to skin metastases 
from primary breast cancer in three patients, and also to mela-
noma lesions in 14 patients; the transgene was detectable at 
messenger RNA (mRNA) and protein levels in all patients.31 
Electrotransfection was used to assist in the delivery of naked 
pDNA to BJMC3879 mouse mammary carcinoma; such a 
method used to deliver IL-12 pDNA significantly delayed 
tumor development in mice, reduced the incidence of lymph 
node metastases by over 50% compared with vector control, 
and resulted in smaller lung metastases.32 Despite impressive 
results that have been generated with electrotransfection, 
the practicality and acceptability issues involved in such 
techniques may lead to patient reluctance. Furthermore, the 
use of naked DNA and techniques such as jet injection are 
limited to disease conditions where tumors are superficial 
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and easy to access. In the majority of disease states, systemic 
therapy delivery is required, necessitating use of a vehicle 
to protect nucleic acids from nuclease attack. Safety and 
immunogenicity issues associated with viral gene therapy 
delivery and the limitations of physical delivery methods 
have led to the development of a range of nonviral delivery 
vehicles, including polymers, liposomes, or peptides, or 
combination thereof, to protect the DNA from degradation 
and ensure that it reaches the nucleus. Of the multitude of 
nonviral delivery options published, it has become clear that 
although the safety issues are much less significant than is 
the case with their viral counterparts, efficacy remains the 
biggest stumbling block.
Nonviral gene therapy strategies are compelled to 
innovate to improve their nucleic acid cargo delivery in 
order to compete with the unrivalled performance of viral 
counterparts.33 Figure 1 details some of the agents that have 
been employed as vehicles for nonviral nucleic acid cargo 
delivery and some of the strategies that have been developed 
to improve delivery. Despite improvements in nonviral gene 
therapy strategies, there has been limited translation of 
impressive laboratory-generated results to the clinical setting 
for the targeting of breast cancer.
tgDCC-E1A is a nonviral therapy that was assessed 
for tolerability and clinical eff icacy in nine patients 
with metastatic breast cancer. The therapeutic nucleic 
acid, pE1A-K2, which encodes E1A, a protein with 
known antitumor activity, is complexed using 3β[N-(N′, 
N′-dimethylaminoethane)-carbamoyl] cholesterol (DC-
Chol) and dioleoylphosphatidylethanolamine (DOPE). E1A 
DNA was detectable in 14 of 15 samples tested following 
direct intratumoral injection of the therapy, although the 
authors were unable to assess mRNA or protein levels 
of E1A. There was some limited evidence of therapeutic 
potential following this initial trial.34 In a separate trial, 
the same therapy was delivered to the pleural cavity of six 
breast cancer patients. The therapy appeared to downregu-
late HER-2 expression in all of the breast specimens tested, 
and increased numbers of apoptotic cells were detected in 
ascites or pleural fluids, compared to those detected prior 
to gene therapy.35
ZYC300 is a pDNA encoding an inactivated form of the 
carcinogen activator cytochrome P450 1B1 (CYP1B1) that 
is complexed in poly-DL-lactide-coglycolide  microparticles. 
The nonviral therapy is aimed at  vaccinating patients against 
CYP1B1, which is expressed on most transformed tissues, 
but is absent from most normal tissues. A Phase I clinical 
trial undertaken to assess the safety, tolerability, and feasibil-
ity, as well as immunologic response and clinical activity of 
ZYC300 treatment comprised 17 patients with advanced can-
cers, one of whom had metastatic breast cancer. The disease 
of the breast cancer patient, whose disease had metastasized 
Plasmid DNA
siRNA
shRNA
Chemotherapy, 
eg, paclitaxel
Functional group, 
eg, HER-2 antibody
Condensing
material,
eg, cationic lipids
and polymers or
fusogenic
peptides
Figure 1 Simplified schematic of nonviral gene therapy delivery vehicle.
Abbreviations: HeR-2, human epidermal growth factor receptor 2; shRNA, short hairpin RNA; siRNA, small interfering RNA.
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to the bone and liver, stabilized after ZYC300 treatment, 
before eventually progressing. ZYC300 proved extremely 
beneficial for a single patient in the trial, whose renal disease 
was regressing at the time of publication of the report.36
Nucleic acid cargo is generally condensed into nano-
particulate formulation using a cationic lipid such as N-[1-
(2,3-dioleyloxy)propyl]-N,N,N-trimethylammonium chloride 
(DOTMA), dioctadecylamidoglycylspermine (DOGS), 
1,2-bis(oleoyloxy)-3-(trimethylammonio)propane (DOTAP), 
DC-Chol, and DOPE, or cationic polymers, which include 
poly(L-lysine) (PLL), polyethylenimine (PEI), chitosan, and 
polyamidoamine (PAMAM). Fusogenic peptides capable of 
delivery of pDNA include KALA.37
Transcriptional control  
of genetic material
A common side effect of most, if not all, cancer therapies is 
damage to tissue that neighbors the diseased tissue. While 
it is usually imperative that maximal achievable delivery of 
therapeutic to the tumor is achieved, therapeutic efficacy 
is often limited by toxicities. It is well-understood that 
cancerous tissue has a genetic signature that differs from 
neighboring, nondiseased tissue. An attractive option for 
the gene therapist is to target these genetic differences in 
order to limit transgene expression to cells that aberrantly 
express certain genes.38 In breast cancer, the HER-2  receptor 
is a commonly targeted genetic aberration, although it is 
only targetable in 20% of breast cancers.39 Identification of 
suitable genes that are aberrantly expressed in breast cancer 
could aid in transcriptional targeting of gene expression in 
the remaining 80% of cases. In this manner, we the authors 
have used the osteocalcin promoter to drive the expression 
of our therapeutic transgene of interest, inducible nitric oxide 
synthase (iNOS), using nonviral means. Using this promoter 
to confine transgene expression to the tumor, we have demon-
strated exquisite tumor abrogation in human prostate cancer 
models.40,41 Identification of further tumor-specific markers 
for promotion of transgene expression may lead to improved 
gene therapy potential and limited toxicities.
One of the earliest targeted nonviral gene therapy clinical 
trials was for patients that overexpress the HER-2 (erbB-2) 
receptor. Targeting was achieved with a HER-2 promoter 
containing a binding site for AP-2, which is an upregulated 
transcription factor in HER-2-positive tumors. The pERCY 
plasmid utilized this promoter to drive expression of cytosine 
deaminase, the enzyme that metabolizes 5-fluorocytosine 
(5-FC) to 5-fluorouracil (5-FU). Twelve patients were selected 
with skin metastases, analyzed for HER-2 expression, and the 
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and were as active as CMV-promoted expression when 
transduced using a recombinant adeno-associated virus 
 vector.45 The human fatty acid synthase promoter, expression 
of which is again limited to transformed tissue, was used to 
drive expression of HSV thymidine kinase in an adenoviral 
vector. SKBR3 cells treated with Ad-FAS-TK therapy before 
implantation into mice failed to develop into tumors, while 
vector controls successfully developed into xenografts.46 
T47D xenograft regression was seen in mice that received 
adenoviral cytosine deaminase gene therapy under tran-
scriptional control of the alpha lactalbumin promoter with 
5-FC; the regression of tumors was of the same magnitude 
as seen when promotion by CMV was performed. Again, 
transgene expression was limited to breast cancer cells, and 
absent from nontransformed MCF10A breast cells and U2OS 
osteosarcoma cells.47
While in principle there are numerous options for control-
ling expression through the use of tumor-specific  promoters, 
the rate-limiting factor is that delivery of naked DNA cor-
relates to extremely poor gene expression and delivery 
vehicles are required for all but the most superficial of lesions. 
Of course, this presents a new set of complex interactions 
that need to be fully characterized in terms of efficiency 
of overcoming the biological barriers, immunogenicity, 
cost-effectiveness, and the probability of gaining regulatory 
approval for human use.
RNA interference therapies
The aim of the majority of the gene therapy strategies above 
has been the delivery of nucleic acid to evoke expression of 
a therapeutic gene. Another viable genetic therapy strategy 
is interference with the expression of unappealing genes. 
siRNA and shRNA can be used for the transient or long-
term abrogation of the expression of a target gene, and have 
themselves received a degree of attention for experimental 
treatment of breast cancer.48 The therapeutic potential of 
siRNA targeting of the survivin gene in 4T1 breast cancer 
xenografts using a nonviral TAT-g-CS was recently reported. 
Nanoparticulate formulations of the therapy delivered 
intratumorally to xenograft-bearing mice evoked significant 
slowing of tumor development.49 A reduction-sensitive linear 
cationic click polymer (RCP) used to deliver shRNA targeting 
the multidrug resistance (MDR) gene restored sensitivity to 
doxorubicin in resistant MCF-7 breast cancer cells in a mouse 
xenograft model. The complexes were delivered systemically, 
and xenograft volume was significantly lessened in mice 
receiving MDR interference plus doxorubicin compared to 
those that received doxorubicin alone.50
nodules were injected with up to 400 μg of naked pERCY 
plasmid followed by systemic administration of 200 mg/kg/24 
hours of 5-FC. Four of the patients showed tumor reduc-
tion, two of whom had received only nucleic acid treatment 
with no prodrug. Cytosine deaminase gene expression was 
confirmed only in tumor tissue with no evidence of off-site 
targeting. However, the authors report that it took more than 
18 months to recruit only 12 patients with nodular cutane-
ous HER-2 expressing lesions, and furthermore there was a 
high variability in cytosine deaminase expression, with the 
majority of patients having low levels at best.42
The survivin promoter was used to promote bax (both 
wild-type and S187del mutant, which has increased activity) 
expression in a range of breast cancer cell lines. Cytotoxicity 
elicited by the survivin promoter-driven bax expression was 
not as potent as that elicited by cytomegalovirus (CMV)-
driven expression in SKBR3, MDA-MB-231, and MCF7 
breast cancer cells. However, bax expression and related cyto-
toxicity was absent in normal cells when the tumor-specific 
promoter was used, but present in the case of CMV-driven 
expression. Intratumoral delivery of the survivin-driven bax 
S187del complexed with in vivo-jetPEI resulted in a tumor 
growth delay that was comparable to that seen in CMV-driven 
expression of the wild-type.43 This sophisticated strategy of 
target (direct tumor transcriptional targeting) and transgene 
optimization (the S187del mutant had 5–6 times more cyto-
toxic potency than the wild-type transgene) highlights the 
options that are available to the enterprising gene therapist.
Transcriptional regulation of gene expression was 
achieved in an elegant approach that employed PEGylated 
PEI polyplexes functionalized with a MUC-1 nanobody. 
The complex was used to deliver the cytotoxic tBid trans-
gene under the control of the MUC-1 promoter, commonly 
overexpressed in cancer. The nanobody/promoter-targeting 
successfully evoked cell killing in MCF-7, T47D, and SKBR3 
breast cancer cells; replacement of the MUC-1 promoter with 
the synapsin 1 promoter (expression of which is confined to 
the central nervous system) abolished the cytotoxic effect 
of the complex, underlining the therapeutic potential of tumor 
promoter targeting.44
Tumor-specific promoters have also been used to improve 
target specificity of viral vectors. PRC1 and RRM2 were 
overexpressed in MCF-7 and T47D breast cancer cell lines, 
compared with nontransformed MCF-10As, and were also 
overexpressed in 48% and 58%, respectively, of tumor 
samples, but not adjacent normal tissue, from a cohort of 
breast cancer patients. Both promoters evoked impressive 
reporter gene expression in MCF-7 and MDA-MB-231 cells, 
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A competitive advantage that nonviral vehicles have over 
viral is the possibility to deliver more than just the nucleic 
acid therapeutic; a cationic core–shell nanoparticle used to 
deliver Bcl-2 siRNA along with paclitaxel resulted in improved 
cytotoxicity toward MDA-MB-231 breast cancer cells in vitro, 
while the same vehicle delivered IL-12 pDNA with paclitaxel, 
and slowed tumor development more efficiently than either 
cargo delivered singly.51 In a separate study, local IL-12 gene 
therapy delivered using a water-soluble lipoprotein (WSLP) 
improved response to systemically delivered paclitaxel in 
4T1 breast cancer xenografts, boosting survival of mice and 
diminishing the number of metastases developed.52
Although the HER-2 receptor is the most popular among 
gene therapy targeting strategies, others are gaining in 
popularity. Targeting the heparin-binding epidermal growth 
factor-like growth factor (HB-EGF) receptor for the delivery 
of siRNA was an effective strategy in HB-EGF-expressing 
MDA-MB-231 in vitro.53 Indirect inhibition of tumor pro-
gression has also been achieved using RNA interference 
technology; when siRNA targeted against vascular endothe-
lial growth factor (VEGF) was delivered using reconstituted 
high-density lipoprotein to mice bearing MCF-7 xenografts, 
significant slowing of tumor progression was noted. The 
systemically delivered therapy evoked downregulation of 
VEGF protein, and a dose-dependent lessening of the num-
ber and density of microvessels in the tumors.54 Similarly, 
impressive results were observed when a core shell nanopar-
ticle was used to deliver VEGF-directed siRNA along with 
paclitaxel. MCF-7 xenograft tumor progression was slowed 
by nonfunctionalized nanoparticles carrying the dual cargo; 
functionalization with vapreotide, a ligand for somatostatin 
receptors, commonly upregulated in cancer, significantly 
improved the response seen in nonfunctionalized therapy. 
Again, tumor microvessel infiltration was repressed in xeno-
grafts that received the VEGF RNA-interfering therapy.55 
Silica nanoparticles carrying p53 and functionalized with 
transferrin achieved impressive tumor growth retardation in 
MCF-7 xenografts,56,57 as did micellar nanoparticles carrying 
acid ceramidase siRNA in BT474 xenografts.57
Use of recombinant multifunctional 
nonviral delivery systems
The delivery strategies detailed above involve complex chemi-
cal and physical processes to develop vehicles capable of 
multifunctionality. The last few years have seen the develop-
ment of recombinant vector technology; competent cells are 
transformed with bio-inspired plasmids that contain motifs 
arranged specifically to render the resultant recombinant 
biomimetic vehicles capable of binding, condensing, and 
delivering nucleic acid cargo to target cells. One such vector 
was generated to contain the adenoviral penton base, which 
is critical for viral internalization and endosome disruption. 
A recombinant gene was constructed to contain wild-type 
Ad5 penton flanked at the N-terminal by a peptide sequence 
for targeting to the HER-2 receptor, and at the C-terminal 
by a decalysine with responsibility for DNA binding and 
condensation. The resultant vehicle was capable of delivering 
reporter gene plasmids to breast cancer cells, and preferen-
tially to those cells that overexpressed HER-2.58 Another 
recombinant vector was used to deliver TNF-related apoptosis-
inducing ligand (TRAIL)59 to ZR-75-1 breast cancer cells. The 
vector contained a DNA-condensing motif, a breast cancer 
cell-targeting peptide, a pH-responsive endosome disruption 
peptide, and a nuclear localization signal. The recombinant 
vehicle condensed pTRAIL DNA into nanoscale particles 
that, when exposed to ZR-75-1 breast cancer cells, evoked 
impressive cell kill (up to 62%).59 Similar technology was 
used to condense and deliver iNOS pDNA to ZR-75-1 breast 
cancer cells in vitro.60 Clonogenic assay analysis revealed 
impressive potency of the recombinant vector complexed with 
iNOS pDNA, with a viable surviving fraction only of 0.4% 
of control after transfection of ZR-75-1.60
Another HER-2 motif-expressing recombinant vector was 
used to target breast cancer, and was capable of preferentially 
targeting a recombinant vector carrying the β-galactosidase 
gene toward MDA-MB-453 breast cancer cells,61 and yet 
another such recombinant protein, KALA-2H1-NLS-TP, that 
differs in the DNA-condensing motif was recently reported 
from the same group.62 While the developments made in the 
designer biomimetic vector are impressive, evaluation of the 
delivery systems in vivo is ultimately required to determine 
their therapeutic potential.
A HER-2 antibody/protamine fusion protein expressed in 
and purified from Escherichia coli was capable of binding and 
delivering siRNA-targeting DNA methyltransferases to BT474 
breast cancer cells. The authors of the study were able to report 
impressive tumor growth delay evoked by intravenous delivery 
of their therapy, resultant of the silencing of DNA methyltrans-
ferases, with consequent restoration of tumor suppressor gene 
function.63 Similarly, intratumoral injection of a tissue factor-
targeting shRNA, complexed using a recombinant system and 
targeted toward the HER-2 receptor, significantly diminished 
tumor progression in an MDA-MB-453 xenograft model in 
mice.64 Low cost and ease of production of these recombinant 
vectors make them highly attractive to the biopharmaceutical 
gene therapist.
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DNA vaccination
Of course, many of the issues with traditional nonviral gene 
therapy are circumvented with DNA vaccination, as there 
is no need for long-term gene expression. Rather, the aim 
is to prime and boost to activate the patient’s own immune 
response to target a particular set of antigens. Issues with 
safety and side effects have rendered conventional patho-
genic vaccines obsolete. Current developments are focused 
on vaccines developed from purified subunits, recombinant 
proteins, or synthetic peptides. Although these vaccines have 
an excellent safety profile, their immunogenic potency can 
be significantly compromised with the induction of only an 
antibody response. For many pathogens, especially intracel-
lular, the effects of these vaccines are minimal. Therefore, 
there is a “need” to activate the cell-mediated immune 
response primarily through cytotoxic T lymphocytes (CTLs). 
It has been well-documented that DNA vaccination is a 
highly potent strategy whereby pDNA encodes a particular 
antigen for a disease.4,65,66 In order for the desired antigen to 
be expressed, the pDNA should be delivered to the nucleus 
of cells to ensure transcription and translation of the protein 
antigen in the cytoplasm of the host cell. The DNA should 
also ideally be delivered to an antigen-presenting cell (APC). 
This is so that the antigen expressed in the cytoplasm can be 
presented to the immune system via the MHC I pathway. The 
consequences of this are that there will be a cell-mediated 
immune response. This renders DNA vaccines much more 
effective than current vaccines in evoking a long-term 
immune response. In addition to a prophylactic response, 
DNA vaccines can also be therapeutic, are inexpensive to 
manufacture, and do not require cold chain storage. Many 
cancers are characterized by tumor-associated antigens 
(TAAs) that provide unique targets for vaccination. Oncept® 
is the first licensed product for cancer in either humans or 
animals for canine melanoma based upon delivery of cDNA 
for human tyrosinase (huTyr), which evokes a greater immune 
response than canine tyrosinase.67
There are a plethora of TAAs that could be potential tar-
gets for breast cancer. Such targets include HER-2, MUC-1, 
CEA, mammaglobin A, and hTERT.68–72 As a transmembrane 
receptor, HER-2 can be easily exposed to humoral and cell-
mediated response. Furthermore, the differential expression 
of HER-2 between breast tumors and normal tissue negates 
the risk of an autoimmune response. The HER-2 DNA 
vaccine was delivered with considerable success to FVB-
huHER-2 transgenic mice that form spontaneous mammary 
tumors. The vaccination consisted of two intramuscular 
injections of 50 μg of chimeric human/rat HER-2 plasmid 
followed by electroporation at 2-week intervals; 65% of mice 
were tumor-free after 90 weeks compared to 45 weeks for 
mock vaccinated controls.73 Frequently though adjuvants 
are also required for a successful immune response. For 
example, patients with metastatic breast cancer were given 
full-length HER-2-pDNA with GM-CSF and IL-2 cytokines 
as adjuvants. The dosing schedule involved three cycles, 
comprising 270 μg HER-2-pDNA delivered intramuscularly 
and 30 μg intracutaneously. Two days prior to receiving the 
vaccine, patients were administered 3×40 μg daily intracuta-
neous injections of GM-CSF molgramostim as an adjuvant. 
In addition, 24 hours after vaccination, IL-2 aldesleukin 
(1 μg/kg) was given to the patients subcutaneously for 4 
consecutive days. There were 4 weeks between each HER-
2-pDNA vaccination. Of the six patients that completed the 
three vaccination cycles, two survived in excess of 4 years, 
and overall, the vaccination was well-tolerated with cell-
mediated and humoral immune responses observed.74
Encouraging results have also been reported with mam-
maglobin-A DNA vaccination. Mammaglobin-A is present 
in up to 80% of primary and metastatic breast cancers and 
expression is not stage dependent, rendering it an ideal target 
for vaccination.71 Narayanan et al demonstrated for the first 
time in vivo that vaccination with mammaglobin-A cDNA 
(four doses of intramuscular injections of 100 μg of cDNA 
at 2-week intervals) resulted in a CD8+ response against 
mammaglobin-A positive tumors, and that passive transfer 
of CD8+ CTLs were able to regress such tumors in vivo.75 
In this instance, there was no electroporation to enhance cel-
lular uptake, and without some sort of delivery assistance, 
cellular uptake can be greatly reduced. Nevertheless, the 
preclinical data demonstrated the efficacy of this vaccine, 
and the mammaglobin cDNA was evaluated in a Phase I 
clinical trial.76 Seven patients with stage IV metastatic breast 
cancer and HLA-A2+ status were given three doses of the 
mammaglobin-A DNA vaccine 28 days apart. Although most 
reports detail the CD8+ and antibody response, this clini-
cal trial focused on the CD4+ population, identified by the 
expression of the inducible costimulator molecule (ICOS) 
on recently activated T-cells. Results indicated a significant 
expansion in CD4+ ICOS T-cells coupled with a reduction in 
regulatory T-cells, which is indicative of antitumor immunity, 
although further studies are required to evaluate the clinical 
outcome.76
Challenges
It is clear from existing preclinical and early-stage trials that 
DNA vaccination holds promise for breast cancer patients 
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but that there are a number of challenges and developments 
required before this becomes an approved product. One of the 
first challenges lies in which TAAs should be selected for a 
DNA vaccine for breast cancer. With an increased emphasis 
on personalized medicine and the screening of biopsies, it 
is possible to create a patient- or tumor-specific DNA vac-
cine where multiple antigens are delivered. In addition, the 
delivery of fusion sequences of DNA coding for more than 
one antigen and adjuvants such as GM-CSF also increases 
the chances of incurring a therapeutic immune response.
Another challenge lies in improving the efficacy of 
the DNA vaccine. Although the “gold standard” mode of 
delivery is currently injection followed by electroporation, 
it is questionable whether this will gain regulatory approval, 
and perhaps more importantly, achieve an acceptable level of 
patient compliance. Given the number of exciting nonviral 
technologies available, it is only a matter of time before a 
relatively straightforward delivery system becomes a front-
runner to replace needle injection and electroporation. Such 
a delivery system should work with the body to overcome the 
extra- and intracellular barriers to deliver the DNA payload to 
the nucleus of the immune cells. Of noteworthy importance, 
however, is the fact that optimal formulations in vitro rarely 
correlate to the optimum immune response in vivo. A study 
by Endmann et al examined the ratios of MIDGE-Th1 
(minimalistic immunogenically defined gene expression) 
DNA vaccine with the cationic lipid SAINT-18 in vitro and 
in vivo. The MIDGE vector resulted in optimal transfection 
in vitro at a DNA:lipid weight per weight ratio of 1:4.8, yet 
in vivo, there was no immune response using the same ratio. 
The highest immune response was found to be at a weight 
per weight ratio of 1:0.5 (MIDGE: SAINT-18).77 Although 
time consuming, once the correct formulation of delivery 
system is determined, the immune response can be greater 
than naked DNA.77 It is likely that such a system could take 
longer to gain regulatory approval but the resultant highly 
potent DNA vaccine should reduce the frequency of admin-
istrations and have a greater chance of being successful.
DNA vaccines are typically plasmids that retain nones-
sential information such as an origin of replication and an 
antibiotic resistance gene. In addition, they are grown in 
genetically modified bacteria, thereby increasing the number 
of quality control issues and manufacturing steps.78 In a DNA 
vaccine, the critical components are a promoter, antigen, and 
polyA sequence, and a study by Walters et al has demonstrated 
that a minimal closed double-stranded linear DNA construct 
can produce comparable humoral and cell-mediated immune 
response to conventional pDNA.79 Touchlight Genetics 
synthesize these “doggybone” DNAs in an enzymatic process 
which should render them highly desirable from a regulatory 
and clinical perspective. Such minimal DNA systems could 
become the future of approved human DNA vaccines.
Conclusion
Generation of an appropriate delivery vehicle is a critical obsta-
cle that needs to be surmounted for a genetic-based therapy to 
be accepted and gain regulatory approval. Despite the progress 
that has been made in more than 40 years of research into using 
nucleic acids as drugs, there are still concerns over the vectors 
used to deliver these therapies. Immunological concerns that 
surround viral delivery, less potent delivery by nonviral meth-
odologies, and concerns over the manufacture of recombinant 
vectors must all be addressed to placate regulatory bodies. The 
recent push for personalized medicine offers opportunities for 
gene therapy researchers, with targeting strategies that were 
highlighted here ripe for exploitation. Ever evolving bioinfor-
matics tools are increasing our knowledge and understanding 
of the genomics of breast cancer, opening new avenues for 
 exploration. Despite this though, the translation of impressive 
bench-generated data has not been as rapid as desired. The 
clinical gene therapies for breast cancer patients documented 
here (both viral and nonviral) were generally well-tolerated, 
with few serious side effects reported. It is hoped that continued 
generation of meaningful preclinical data and delivery vector 
improvement will lead to advancements of clinical testing of 
gene therapies for breast cancer patients.
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